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Introduction
Canakinumab (CAN), a fully human selective anti-IL-1b
monoclonal antibody, has been shown to be efficacious
in systemic juvenile idiopathic arthritis (SJIA), resulting
in significantly longer times to flare vs. Placebo (PBO).
Objectives
1) To explore the relationship between SJIA flare reduc-
tion and CAN exposure (4 mg/kg/every 4 weeks) with
consideration of patient baseline characteristics using a
discrete hazard (flare) simulation model. 2) To predict
the effects of body weight-tiered CAN dosing regimens
at 1 to 6 mg/kg every 4 weeks on SJIA flare rates com-
pared with PBO.
Methods
Plasma concentrations were modeled for patients treated
with CAN (n = 50) or PBO after CAN treatment (n =
50) and used to predict flare risk by a validated and qua-
lified simulation of the CAN exposure-flare hazard rela-
tionship. The model considered both PBO and CAN
treatments and multiple covariates, including baseline
steroid dose, heterogeneity of the population with respect
to disease severity (which had a varying influence on risk
of an early flare), and declining CAN concentrations over
time due to washout in patients on PBO (after receiving
CAN). The final simulation model was also used to
explore the dose-response relationship between SJIA flare
hazard and CAN dose in a simulated trial (1000 simula-
tions), that modeled 700 patients randomized to 1 of 7
treatment arms: PBO, 1 mg/kg, 2 mg/kg, 3 mg/kg, 4 mg/
kg, 5 mg/kg, and 6 mg/kg (all every 4 weeks) of CAN.
Results
The final simulation model successfully re-produced the
Kaplan-Meier curves observed in the phase III program,
with significant differences in flare hazard (p < 0.001)
between treatment arms. Higher CAN plasma concentra-
tions were associated with lower flare hazard. Differences
in the corticosteroid dose at baseline, age, gender, body
weight, daily steroid usage, and level of adapted ACR
response to CAN were not significant predictors of flare
risk. Based on simulation, the probability of flare (90%
CI) over 12 months was 63% (55%, 71%) for the PBO
arm. CAN at 4 mg/kg/every 4 weeks reduced the flare
rate over PBO by 39% (28%, 49%), consistent with the
clinical data observed. Based on simulation, CAN at 1, 2,
3, 4, 5, and 6 mg/kg every 4 weeks was associated with
annual flare rates of 37% (28%, 47%), 30% (24%, 38%),
26% (21%, 33%), 24% (19%, 30%), 22% (17%, 27%), and
21% (16%, 26%), respectively. Relative to the approved
CAN dose, the model predicted a change in flare prob-
ability of +13%, +6%, +2%, -2%, and -3% for the 1, 2, 3,
5, and 6 mg/kg every 4 weeks doses, respectively.
Conclusion
The simulations support 4 mg/kg every 4 weeks as the
appropriate dose for preventing SJIA flare events. Doses
greater than 4 mg/kg provide only marginal gain in flare
reduction over 12 months, while doses less than 4 mg/
kg relatively increase the risk of experiencing a flare.
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